A Chinese scientist reviewing laboratory equipment

Research news

This section contains news items that were not issued as a press release.

Thursday, 23 August 2012
First agreements concluded under WIPO Re:Search for  research on Neglected Tropical Diseases Research to develop treatments for neglected tropical diseases received a boost this week as AstraZeneca concluded agreements through WIPO Re:Search with iThemba Pharmaceuticals (South Africa), the University of California (U.S), and the University of Dundee (UK).
Thursday, 16 August 2012
Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca Under the terms of the agreement, AstraZeneca will make a $28M payment which includes an equity investment and an upfront payment to Regulus.
Thursday, 12 July 2012
AstraZeneca acquires neuroscience assets from Link Medicine LONDON, UK, 12 July, 2012  ̶  AstraZeneca today announced that it has acquired a portfolio of neuroscience assets from Link Medicine Corporation, a privately held biopharmaceutical company based in Massachusetts, USA. Link Medicine has focused its research and development efforts in the field of autophagy, an intracellular process that clears and recycles misfolded proteins and has been developing potential new treatments for a range of neurodegenerative diseases.
Thursday, 12 July 2012
AstraZeneca and leading academic scientists to collaborate on Alzheimer's disease research New A5 Alliance, Led by Dr. Steven Paul, to Study Risk Factor for Alzheimer’s Disease
Monday, 2 July 2012
AstraZeneca and Cellworks Collaborate to find new treatment for Turberculosis AstraZeneca and Cellworks today announced a collaboration supported by the Wellcome Trust to speed the design of novel combination therapies for the treatment of drug-sensitive and resistant tuberculosis. This collaboration will also pave the way for the creation of platforms and approaches to handle Multi Drug Resistant Tuberculosis (MDR-TB), a condition that is reaching epidemic proportions in many developing parts of the world.
Saturday, 30 June 2012
Bristol-Myers Squibb and AstraZeneca expand diabetes alliance through Bristol-Myers Squibb’s acquisition of Amylin Pharmaceuticals Bristol-Myers Squibb Company and Amylin Pharmaceuticals, Inc. announced today that Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of approximately $5.3 billion. The total value of the transaction, including Amylin’s net debt and a contractual payment obligation to Eli Lilly and Company, together totalling about $1.7 billion, is approximately $7 billion. The acquisition has been unanimously approved by the boards of directors of Bristol-Myers Squibb and Amylin. The board of directors of Amylin has unanimously recommended that Amylin’s stockholders tender their shares to the tender offer.
Monday, 25 June 2012
Seven Pharmaceutical Companies Join Academic Researchers to Speed TB Drug Discovery Groundbreaking partnership seeks rapid cure to reduce treatment time from six months to one month
Thursday, 21 June 2012
AstraZeneca completes acquisition of Ardea Biosciences AstraZeneca today announced that on Tuesday 19 June 2012 it completed its acquisition of San Diego, California-based biotechnology company Ardea Biosciences, Inc. The merger was approved by Ardea’s stockholders.
Tuesday, 19 June 2012
AstraZeneca and Rigel sign Worldwide license agreement for a potential new treatment for chronic Asthma AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel’s inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma.  In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function.
Tuesday, 12 June 2012
Five additional pharmaceutical companies have joined a National Institutes of Health’s effort to help scientists research promising new treatments for patients. The programme is focused on discovering new therapeutic uses for existing molecules – a collaboration AstraZeneca already joined earlier this year.